Ribon Therapeutics doses first patient in RBN-2397 Phase 1 trial
Category: #health  By Pankaj Singh  Date: 2019-09-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Ribon Therapeutics doses first patient in RBN-2397 Phase 1 trial
  • The Phase 1 clinical trial assessing RBN-2397 will be the first clinical evaluation of monoPARP Inhibitor.
     
  • RBN-2397 is the company’s PARP7 inhibitor and is capable of potently inhibiting cancer cell proliferation.

Ribon Therapeutics, a biotech company involved in the development of cutting-edge therapeutics that targets novel enzyme families that are activated by cellular stress conditions, recently announced that it dosed the first patient in a Phase 1 clinical trial that assesses RBN-2397, which is its first-in-class PARP7 inhibitor.

Apparently, PARP7 belongs to an enzyme family that gets activated by cellular stress conditions, called the monoPARPs, that are different from polyPARPs like PARP1/2. New research pioneer by Ribon has exhibited that monoPARPs as the main regulators of responses to stress and have been linked to the formation of diseases like cancer.

Chief Medical Officer at Ribon Therapeutics, Sudha Parasuraman, M.D., said that the company is aiming to target PARP7 with the help of RBN-2397, PARP7 plays an important role in the survival of cancer cells. Inhibiting PARP7 has the ability to potently inhibit the proliferation of cancer cells as well as release a ‘brake’ which the cancer cells utilize to evade the immune system.

Parasuraman further continued that the company has seen a strong preclinical evidence that supports RBN-2397’s clinical potential and also believes that the inhibitor could prove to be a valuable treatment option for patients suffering from cancer.  

Chief Executive Officer and President at Ribon Therapeutics, Victoria Richon, Ph.D., said that bringing in the company’s lead compound in the clinic is a major milestone for Ribon and it demonstrates the company’s ability to advance the program initiation into a clinic within three years. The progress shown by Ribon validates the efficiency and utility of the company’s platform which has rapidly been involved in the development of clinical drug candidates and interrogation of novel biological pathways.

Richon further added, the platform has a wide potential application that enables the company to develop top-of-the-line therapeutics to fight an increasing set of targets in neurodegeneration, inflammatory disease and oncology.

 

Source Credit- https://ribontx.com/ribon-therapeutics-announces-dosing-of-first-patient-in-phase-1-clinical-trial-of-rbn-2397-a-first-in-class-parp7-inhibitor/



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Emergency Care Partners finalizes its merger with Chicago’s IEMS
Emergency Care Partners finalizes its merger with Chicago’s IEMS
By Pankaj Singh

With rising cases of roadside accidents worldwide, the need for emergency medical facilities have increased considerably in recent years. These facilities offer immediate assistance without any appointments, which make...

Zelegent expands to OSA therapeutics with MISH platform acquisition
Zelegent expands to OSA therapeutics with MISH platform acquisition
By Pankaj Singh

  • MISH Technology stands for Minimally Invasive Suspension of the Hyoid and is a novel pre-clinical product line meant to treat obstructive sleep apnea (OSA).
  • SunGen Pharma and Elite Pharmaceuticals file an ANDA with the FDA
    SunGen Pharma and Elite Pharmaceuticals file an ANDA with the FDA
    By Pankaj Singh

    This is the second ANDA filed by both the companies, giving Elite Pharmaceutical the exclusive right to retail the drug.

    Elite Pharmaceuticals, Inc. a pharmaceutica...